The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma

Autor: Irena Gribovskaja-Rupp, Paolo Goffredo, Muneera R. Kapadia, Alan F. Utria, Imran Hassan, Jennifer Hrabe
Rok vydání: 2019
Předmět:
Adult
Male
Subset Analysis
Oncology
medicine.medical_specialty
Databases
Factual
genetic structures
medicine.medical_treatment
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
cardiovascular diseases
Stage (cooking)
Aged
Retrospective Studies
Aged
80 and over
Chemotherapy
business.industry
Standard treatment
Confounding
Gastroenterology
Anal Squamous Cell Carcinoma
Cancer
Chemoradiotherapy
Middle Aged
Anus Neoplasms
equipment and supplies
medicine.disease
Survival Analysis
Treatment Outcome
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
cardiovascular system
Female
030211 gastroenterology & hepatology
Surgery
business
Follow-Up Studies
circulatory and respiratory physiology
Zdroj: Journal of Gastrointestinal Surgery. 23:712-719
ISSN: 1873-4626
1091-255X
DOI: 10.1007/s11605-018-04068-x
Popis: The standard treatment for anal squamous cell carcinoma (ASCC) is multiagent chemotherapy with radiation (CRT). This is based on several randomized trials demonstrating lower recurrence and colostomy-free survival rates with multiagent CRT; however, these studies could not confirm an overall survival (OS) benefit. We hypothesized that the lack of improved OS was due to limited sample sizes and follow-up, and that multiagent CRT is associated with higher OS. The National Cancer Database was queried for patients diagnosed with stages I, II, and II ASCC and received between 45 and 59.4 Gy of radiation between 2004 and 2015. OS of patients receiving multiagent CRT compared to monoagent CRT and radiation alone was analyzed across stages. A total of 10,438 patients received multiagent CRT, 1163 had monoagent CRT and 446 received radiation alone. Compared to the other two groups, patients receiving multiagent CRT were younger, had fewer comorbidities, and more advanced disease (all p
Databáze: OpenAIRE
Externí odkaz: